Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$64.20T
24h Vol:
$9.05B
Dominance:
MSFT:4.79%
Stocklytics Platform
Instrument logo  PFE
Pfizer
PFE
55 / 100
S&P500
$28.44arrow_drop_up1.53%$0.43

Performance History

Stocklytics logo
Key Stats
Open$28.24
Prev. Close$28.18
EPS-0.05
Dividend$1.66
Next Earnings DateSep 27, 2024
Dividend Yield %6.05%
Market Cap$157.24B
PE Ratio-
LOWHIGH
Day Range27.92
28.28
52 Week Range25.20
40.37
Ratios
P/B Ratio1.65
Revenue$58.49B
Operating M. %31.52%
Earnings$2.13B
Earnings Growth %-93.21%
EBITDA Margin %16.14%
ROE %2.35%
EPS-0.05

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

55vs 56. Market Avg.

All Score 55 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

PFEMARKET
Value5238
Quality3140
Ownership3017
Growth6046
Dividends4937
check_circle

Pfizer 's Earnings growth forecast for the next quarter of 4.24% is great compared to market average of 0.31%. This indicates PFE could have significant growth.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$760.00
24H (%)arrow_drop_down1.49%
24H ($)-$11.54
MARKET CAP$739.19B
PRICE$512.81
24H (%)arrow_drop_up1.13%
24H ($)$5.78
MARKET CAP$453.09B
PRICE$149.91
24H (%)arrow_drop_up0.04%
24H ($)$0.06
MARKET CAP$357.92B
PRICE$130.06
24H (%)arrow_drop_down0.13%
24H ($)-$0.17
MARKET CAP$322.98B

About Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Drug Manufacturers—General
CEO
Dr. Albert Bourla D.V.M., DVM, Ph.D.
Headquarters
New York
Employees
83000
Exchange
NYSE
add Pfizer  to watchlist

Keep an eye on Pfizer

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Pfizer 's (PFE) price per share?

The current price per share for Pfizer (PFE) is $28.01. The stock has seen a price change of -$0.17 recently, indicating a -0.6% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Pfizer (PFE)?

For Pfizer (PFE), the 52-week high is $40.37, which is 44.13% from the current price. The 52-week low is $25.2, the current price is 11.15% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Pfizer (PFE) a growth stock?

Pfizer (PFE) has shown an average price growth of 0.41% over the past three years. It has received a score of 40 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Pfizer as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Pfizer (PFE) stock price performance year to date (YTD)?

As of the latest data, Pfizer (PFE) has a year-to-date price change of -5.79%. Over the past month, the stock has experienced a price change of 8.31%. Over the last three months, the change has been 1.27%. Over the past six months, the figure is -3.35%. Looking at a longer horizon, the five-year price change stands at -30.96%.

help
Is Pfizer (PFE) a profitable company?

Pfizer (PFE) has a net income of $2.13B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 50.06% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 31.52% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $58.5B, although specific revenue growth data is currently not available. The gross profit is $29.28B. Operating income is noted at $4.24B. Furthermore, the EBITDA is $14.45B.

help
What is the market capitalization of Pfizer (PFE)?

Pfizer (PFE) has a market capitalization of $157.25B. The average daily trading volume is 54.39M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.